

Corporate Sponsored Presentations

Abstract #/Title/Lead Author	Type/Session Category & Title	Session Time/Location
7528 / Brentuximab Vedotin ECHELON-1 Brentuximab vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study Lead Author: H. Crosswell	Poster Presentation Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia	Friday, June 4, 2021 On demand, 9:00 am ET
TPS7571 / Brentuximab Vedotin SGN35-031 TIP Brentuximab vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (SGN35-031, Trial in Progress) Lead Author: N. Bartlett	Poster Presentation Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia	Friday, June 4, 2021 On demand, 9:00 am ET
4528 / Enfortumab Vedotin EV-103 Cohort A Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC) Lead Author: T. Friedlander	Poster Presentation Genitourinary Cancer—Kidney and Bladder	Friday, June 4, 2021 On demand, 9:00 am ET
4524 / Enfortumab Vedotin EV-201 Cohort 2 Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2 Lead Author: B. McGregor	Poster Presentation Genitourinary Cancer—Kidney and Bladder	Friday, June 4, 2021 On demand, 9:00 am ET
4539 / Enfortumab Vedotin EV-301 Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy Lead Author: R. Mamtani	Poster Presentation Genitourinary Cancer—Kidney and Bladder	Friday, June 4, 2021 On demand, 9:00 am ET
TPS4587 / Enfortumab Vedotin EV-304 TIP KEYNOTE-B15/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) (Trial in Progress) Lead Author: C. Hoimes	Poster Presentation Genitourinary Cancer—Kidney and Bladder	Friday, June 4, 2021 On demand, 9:00 am ET
1043 / Tucatinib HER2CLIMB Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB) Lead Author: G. Curigliano	Poster Presentation Breast Cancer—Metastatic	Friday, June 4, 2021 On demand, 9:00 am ET
TPS315 / Tucatinib SGNTUC-019 TIP SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (Trial in Progress) Lead Author: T. Stinchcombe	Poster Presentation Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Friday, June 4, 2021 On demand, 9:00 am ET
TPS1097 / Tucatinib HER2CLIMB-04 TIP HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, Trial in Progress) Lead Author: I. Krop	Poster Presentation Breast Cancer – Metastatic	Friday, June 4, 2021 On demand, 9:00 am ET
1044 / Tucatinib 380-IST-004 Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer Lead Author: E. Stringor-Reasor	Poster Presentation Breast Cancer – Metastatic	Friday, June 4, 2021 On demand, 9:00 am ET
TPS595 / Tucatinib CompassHER2 RD TIP A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer (Trial In Progress) Lead Author: C. O'Sullivan	Poster Presentation Breast Cancer—Local/Regional/Adjuvant	Friday, June 4, 2021 On demand, 9:00 am ET
TPS5596 / Tisotumab Vedotin innovaTV 301 TIP Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT cx12/GOG 3057, Trial in Progress) Lead Author: I. Vergote	Poster Presentation Gynecologic Cancer	Friday, June 4, 2021 On demand, 9:00 am ET
TPS3144 / SGN-B6A SGNB6A-001 TIP A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress) Lead Author: A. Patnaik	Poster Presentation Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Friday, June 4, 2021 On demand, 9:00 am ET
TPS2657 / SEA-TGT SGNTGT-001 TIP SGNTGT-001: A Phase 1 Study of SEATGT, an Effector-Function Enhanced Monoclonal Antibody (mAb), in Advanced Malignancies (Trial in Progress) Lead Author: E. Garralda	Poster Presentation Developmental Therapeutics—Immunotherapy	Friday, June 4, 2021 On demand, 9:00 am ET